Icon Bioscience's Series B Round

Icon Bioscience raised a round of funding on August 28, 2013. Investors include Signet Healthcare Partners.

Icon Bioscience (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome. IBI's…

Articles about Icon Bioscience's Series B Round: